Compare OMH & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMH | LGVN |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 24.7M |
| IPO Year | 2022 | 2021 |
| Metric | OMH | LGVN |
|---|---|---|
| Price | $0.64 | $0.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 126.6K | ★ 235.1K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | $28.40 | N/A |
| Revenue Next Year | $23.07 | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.51 | $0.48 |
| 52 Week High | $1.91 | $1.80 |
| Indicator | OMH | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 41.87 | 53.30 |
| Support Level | $0.51 | $0.73 |
| Resistance Level | $1.38 | $0.84 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 54.34 | 69.03 |
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.